PGI12 Economic Burden and Quality of Life of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In Germany: Results From The Ibis-C Study  by Layer, P et al.
A624  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
impairment: 36.3%±24.8%. The most prevalent symptoms at baseline were abdominal 
pain (85.3%), constipation (7.5%) and bloating (76.5%). Mean IBS-QoL was 61.8±18.2 
(scale: 0-100 [worst-best]). Mean EQ-5D was 58.4±20.2 (scale: 0-100 [worst-best]) and 
85.3% and 50.9% of patients reported moderate-to-severe problems in pain/discom-
fort and anxiety/depression, respectively. Over the year, 78.4% patients consulted 
a primary care physician and 69.6% a gastroenterologist, 18.6% patients required 
emergency department visits/hospitalisation and 66.7% had a diagnostic test. 54.9% 
patients took prescription drugs for their IBS-C and 69.6% took non-prescription 
drugs. Mean (95%CI) annual direct costs per patient for Germany’s national health-
care system: € 1,423 (621-2601); cost for the patient: € 539 (313-841); indirect cost: € 2,619 
(1400-4131). The total annual cost: € 4,581 (2935-6569). ConClusions: Moderate-to-
severe IBS-C symptoms greatly impact German QoL and work productivity. Current 
management practices result in high direct and indirect costs. This results in signifi-
cant cost to both the German national healthcare service and the patient, with the 
latter assuming one quarter of all direct medical costs.
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objeCtives: Ulcerative colitis and Crohn´s disease, have a significant impact 
on health care budget. The aim of this study was to estimate costs of treatment 
and utilization of resources by patients with inflammatory bowel disease (IBD) in 
Serbia. Methods: We performed a population-based, cost of illness study to iden-
tify direct, indirect and out of pocket costs of treatment of patients with IBD from 
societal perspective. Patients with Crohn´s disease (n = 59) and patients with ulcera-
tive colitis (n = 53) completed semi-structured questionnaire with data about utiliza-
tion of heath resources and illness-related expenditures. All costs were calculated 
in Republic of Serbia dinars (RSD), at one-year level. Results: Total direct costs 
per patient-year in group with Crohn´s disease were 1.602,97 Euro (192.614,32 RSD) 
and total indirect costs per patient-year in group with Crohn’s disease were 233,13 
Euro (28.014,00 RSD). Total direct costs per patient-year in group with ulcerative 
colitis were estimated on 1.183,97 Euro (142.267,15 RSD) and total indirect costs per 
patient-year in group with ulcerative colitis were estimated on 178,39 Euro (21.436,00 
RSD). The greatest part od direct costs were incurred by hospitalization (52.350,00 
RSD per patient-year for Crohn’s disease, and 47.895,00 RSD for ulcerative colitis), 
due to prolonged stay in a hospital (31 days per patient-year for Crohn’s disease, 
and 34 days for ulcerative colitis). ConClusions: Costs of IBD in Serbia are lower 
than in developed countries for two reasons: relatively expensive biologic therapy 
is under-utilized, and prices of health services largely used by the IBD patients are 
controlled by state on a very low level.
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objeCtives: The aims of our multicenter study were to quantify direct medical 
costs during interferon (IFN)-based antiviral treatment and per sustained viro-
logical response (SVR) among patients with chronic hepatitis C-virus (HCV) infec-
tion and advanced hepatic fibrosis in the Netherlands, Germany, Switzerland and 
Canada. Methods: Direct medical costs were quantified during IFN-based treat-
ments received by all consecutive patients (N= 455) with chronic HCV infection and 
biopsy-proven bridging fibrosis or cirrhosis (Ishak scores 4-6). The components of 
care from initiation of therapy were quantified by three distinct categories: treat-
ment, safety-monitoring and complications. Total medical costs attributable to each 
cost component were calculated and expressed in 2013 Euros. Sensitivity analyses 
were performed to explore the influence of components of care and the SVR rate 
on medical costs. Results: In total, 672 IFN-based treatments, administered to 455 
patients, were included in the analysis. At time of inclusion, median age was 48 
years (IQR 43–56), 317 (70%) patients were male, and 346 (76%) presented with cir-
rhosis. Platelet counts were available for 432 (95%) patients, of whom 226 (52%) had 
thrombocytopenia. Total mean medical costs per treatment were € 14,559 (95% CI, 
€ 13,323-€ 15,836). Among patients with a normal platelet count and thrombocytopenia, 
mean costs were € 12,419 (95%CI, € 10,974-€ 13,937) and € 14,416 (95%CI, € 12,503-€ 16,598), 
respectively. The costs per SVR were € 26,105 (95%CI, € 23,068-€ 29,296) for patients 
with normal platelet counts and € 50,907 (95%CI, € 44,151-€ 59,612) for patients with 
thrombocytopenia. In patients with severe thrombocytopenia (platelet count below 
100*109/L) the costs per SVR were € 74,961 (95%CI, € 55,463-€ 103,541). The correspond-
ing SVR rates were 48%, 28% and 18%, respectively. Sensitivity analyses confirmed 
the robustness of our results. ConClusions: Real-world medical costs did not differ 
significantly among patients with or without thrombocytopenia. However, the SVR 
rate was lower among patients with severe thrombocytopenia, in whom the medical 
costs per SVR with IFN-based therapy were substantial.
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heterogeneous extensive metabolizer, which had the incremental cost effectiveness 
ratio of ¥57,810 per QALY gained. Probabilistic sensitivity analysis suggests that 
the results are robust with 97% probability that ilaprozole is consider cost effective 
when 3 times China average GDP per capital threshold is used. ConClusions: The 
cost-effectiveness analysis results demonstrated that ilaprazole would be consid-
ered cost-effective compared with omeprazole to treat newly diagnosed duodenal 
ulcer patient in China. When treating the duodenal ulcer patients who are CYP2C19 
subpopulation of heterogeneous extensive metabolizer, ilaprazole is highly cost-
effective, compared with omeprazole.
PGI10
strenGths anD weaknesses of CUrrent ClInICal anD eConomIC 
evIDenCe for the ComParIson of laParosCoPIC versUs oPen rePaIr of 
InCIsIonal hernIa
Hargreaves JA
Covidien (UK) Commercial Ltd, now part of Medtronic, Whiteley, Fareham, UK
objeCtives: Incisional hernias are common following abdominal surgery and place 
a significant burden on patients and healthcare resources. There are two main 
approaches to mesh-based surgical repair of an incisional hernia: open surgery 
and laparoscopy. To date, however, no consensus has been reached as to which 
approach is preferred. The aim of this study was to review the strengths and weak-
nesses of current clinical and economic evidence comparing laparoscopic with open 
repair of incisional hernias. Methods: Studies investigating clinical and economic 
outcomes of laparoscopic and open incisional hernia repair published between 
2003–2014 were identified. Due to the paucity of available data, evidence is supple-
mented using findings from large database studies. Other types of study were con-
sidered for specific outcomes only when no other evidence was available. Results: 
Overall, there is a relatively large body of consistent evidence to conclude that 
laparoscopic repair of incisional hernia is at least equal to open repair in terms of 
mortality, short- to medium-term recurrence, complications, pain and quality of life, 
with a possibly longer operative time. In addition, laparoscopic repair of incisional 
hernia has consistently been shown to be associated with fewer infections and a 
shorter hospital stay than open repair. Although economic data are limited, there 
is consistent evidence from studies that compared the costs for both laparoscopic 
and open repair of incisional/ventral hernia to suggest that the higher operational 
costs associated with laparoscopic repair, which have been attributed, variously, to 
a longer operative time, a need for more expensive mesh or greater supply costs in 
several studies appear to be offset by the shorter hospital stay associated with the 
procedure. ConClusions: There is consistent evidence to suggest that laparo-
scopic repair is associated with lower rates of infection and shorter hospital stays 
(and consequently lower overall costs) than open surgery.
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objeCtives: To perform comparative pharmacoeconomic study of the applica-
tion of IV generation of pancreatin drugs in patients with pancreatic exocrine 
insufficiency on the hospital stage of medical care. Methods: A pharmacoeco-
nomic model of administration of IV generation of pancreatin drugs (creon and 
ermital) in adult patients (100 persons in compared groups) during replacement 
therapy of pancreatic functional insufficiency was developed. Dosage of the drugs 
was at least 100 000 units of lipolytic activity per 24 h. Time horizon was 21 days. 
Measures of clinical efficiency of the applied therapy were the number of patients, 
who would reach clinical response according to „pain relief” and „diarrhea relief” 
parameters. Results: In the modeled conditions, costs of drug therapy per patient 
were within the range of 962.78 — 1,869.56 RUB in the group of creon and 736.12 
— 1,237.20 for ermital, depending on the dose. CER values were: pain relief in the 
range of 1,046.5 — 2,032.13 in creon group, and 836.50 — 1,405.90 in ermital group; 
diarrhea relief was in the range of 927.38 — 1,927.38 in creon group and 783.10 — 
1,316.17 in ermital group. ConClusions: The conducted clinical and economical 
research demonstrated pharmacoeconomic advantages of ermital administration. 
It should be noted that the results of this work were significantly influenced by the 
applied dosages of medications, which were one of the key factors of economical 
substantiation of use of the considered medical technologies.
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objeCtives: To assess the socio-economic burden of moderate-to-severe IBS-C in 
six European countries (France, Germany, Italy, Spain, Sweden and UK). Here we 
present the economic and quality of life (QoL) results from Germany. Methods: 
Observational, retrospective-prospective (6 months each) study of patients diagnosed 
in the last five years with IBS-C (Rome-III criteria) and with moderate-to-severe dis-
ease at inclusion (IBS-Symptom Severity Scale [IBS-SSS] score ≥ 175). The primary 
objective was to determine annual direct and indirect costs. Secondary objectives 
included assessing QoL at baseline: IBS-QoL and EuroQoL-5D (EQ-5D) question-
naires. Work productivity was assessed using the Work Productivity and Activity 
Impairment:IBS-C questionnaire (WPAI:IBS-C). Results: 102 patients were included 
from Germany: mean (±SD) age 47.6±18.1 years, 83.3% female, 43.1% severe (IBS-SSS). 
In the week prior to baseline, mean presenteeism (WPAI:IBS-C) was: 35.6%±28.2% of 
time; absenteeism: 14.7%±28.2%; work productivity loss: 44.1%±32.7%; daily activity 
